OncoMatch/Clinical Trials/NCT07188090
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Is NCT07188090 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Plerixafor and Gcsf for multiple myeloma.
Treatment: Plerixafor · Gcsf — This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Prior therapy
Must have received: stem cell mobilization (G-CSF, plerixafor, G-CSF biosimilars) — mobilization
Patients must have undergone stem cell mobilization with the combination of G-CSF or biosimilars with plerixafor or G-CSF or biosimilars alone
Lab requirements
Kidney function
serum creatinine ≤ 2.0 mg/dl and/or creatinine clearance of > 40 ml/min (excludes multiple myeloma patients receiving high dose melphalan conditioning)
Liver function
serum bilirubin <1.8, ast or alt < 2.5x upper limit of normal
Cardiac function
lvef of ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Thomas Jefferson University Hospital · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07188090 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received stem cell mobilization.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages